Evolving The Retinal Landscape


Iveric Bio is committed to developing innovative therapies that address unmet needs of patients suffering from the progressive symptoms of common and rare retinal diseases.

Innovations for Tomorrow's Retinal Disease Patients

With a diverse portfolio of therapeutic candidates at different stages of development, our pipeline is focused on bringing innovative treatments for retinal diseases to those who need them most.

For details on our pipeline, including our lead product candidate, Zimura®, click on the programs listed below.

Therapeutics

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Zimura: GA Secondary to AMD
Zimura: Autosomal Recessive Stargardt Disease
IC-500: GA Secondary to AMD

AAV Gene Therapy

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
IC-100: RHO-adRP
IC-200: Best1 Related Retinal Diseases
miniCEP290: LCA10
miniABCA4: STGD1*
miniUSH2A: USH2A
-RELATED IRDs*
*We have an option to exclusively in-license intellectual property resulting from ongoing sponsored research.
Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More